An ASH That Moves The Ball – And The Ticker Price

The American Society of Hematology meeting showcased breakthroughs and some ho-hum news, resulting in rollercoaster-like crests and troughs for biotech stocks.

Hitting bigger business target

In a year of notable advances in blood cancer and gene therapy, the American Society of Hematology (ASH) annual meeting Dec. 9-12 presented the opportunity for drug companies to showcase their latest advances. Big news on potentially paradigm-changing medicines were rewarded as investors clung on for a soaring ride, while Wall Street's reaction to less-than-stellar news coming out of ASH was about as blustery as the December snowstorm that hit Atlanta on the opening day.

Biotech stocks relying on the success of one or two late-stage products experienced big stock fluctuations on Monday morning after the busy weekend of data releases. bluebird bio Inc.'s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By 

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.